▶Rifadin(Sanofi)
Rifampicin 150 mgRifadin 150 mg capsules| 100 capsuleP
£ 18. 32 DT = £ 50. 49
Rifampicin 300 mgRifadin 300 mg capsules| 100 capsuleP
£ 36. 63 DT = £ 123. 87
▶Rimactane(Sandoz Ltd)
Rifampicin 300 mgRimactane 300 mg capsules| 60 capsuleP
£ 21. 98
Powder and solvent for solution for infusion
ELECTROLYTES:May contain Sodium
▶Rifadin(Sanofi)
Rifampicin 600 mgRifadin 600 mg powder and solvent for solution
for infusion vials| 1 vialP£ 9. 20Rifampicin with isoniazid
The properties listed below are those particular to the
combination only. For the properties of the components
please consider, rifampicin p. 364 , isoniazid p. 367.lINDICATIONS AND DOSE
Treatment of tuberculosis (continuation phase)
▶BY MOUTH
▶Child:Although not licensed in children, consideration
may be given to use ofRifinah®in older children,
provided the respective dose of each drug is
appropriate for the weight of the child (consult local
protocol).
DOSE EQUIVALENCE AND CONVERSION
▶Rifinah®Tablets contain rifampicin and isoniazid; the
proportions are expressed in the form x/y where x and y
are the strengths in milligrams of rifampicin and
isoniazid respectively.
▶EachRifinah® 150 / 100 Tablet contains rifampicin
150 mg and isoniazid 100 mg.
▶EachRifinah® 300 / 150 Tablet contains rifampicin
300 mg and isoniazid 150 mg.lUNLICENSED USENot licensed for use in children.
lINTERACTIONS→Appendix 1 : isoniazid.rifampicin
lPATIENT AND CARER ADVICE
Medicines for Children leaflet: Isoniazid and rifampicin
combination for latent tuberculosiswww.medicinesforchildren.
org.uk/isoniazid-and-rifampicin-combination-latent-
tuberculosislMEDICINAL FORMS
There can be variation in the licensing of different medicines
containing the same drug.
Tablet
CAUTIONARY AND ADVISORY LABELS8, 14, 23
▶Rifinah(Sanofi)
Isoniazid 100 mg, Rifampicin 150 mgRifinah 150 mg/ 100 mg
tablets| 84 tabletP£ 19. 09
Isoniazid 150 mg, Rifampicin 300 mgRifinah 300 mg/ 150 mg
tablets| 56 tabletP£ 25. 22Rifampicin with isoniazid and
pyrazinamide
The properties listed below are those particular to the
combination only. For the properties of the components
please consider, rifampicin p. 364 , isoniazid p. 367 ,
pyrazinamide p. 368.lINDICATIONS AND DOSE
Initial treatment of tuberculosis (in combination with
ethambutol)
▶Child:Although not licensed in children, consideration
may be given to use ofRifater®in older children,
provided the respective dose of each drug isappropriate for the weight of the child (consult local
protocol).
DOSE EQUIVALENCE AND CONVERSION
▶Tablet quantities refer to the number ofRifater®
Tablets which should be taken. EachRifater®Tablet
contains isoniazid 50 mg, pyrazinamide 300 mg and
rifampicin 120 mg.lUNLICENSED USENot licensed for use in children.
lINTERACTIONS→Appendix 1 : isoniazid.pyrazinamide.
rifampicinlMEDICINAL FORMS
There can be variation in the licensing of different medicines
containing the same drug.
Tablet
CAUTIONARY AND ADVISORY LABELS8, 14, 22
▶Rifater(Sanofi)
Isoniazid 50 mg, Rifampicin 120 mg, Pyrazinamide
300 mgRifater tablets| 100 tabletP£ 26. 34ANTIMYCOBACTERIALS›OTHER
Cycloserine
lINDICATIONS AND DOSE
Tuberculosis resistant to first-line drugs, in combination
with other drugs
▶BY MOUTH
▶Child 2–11 years:Initially 5 mg/kg twice daily (max. per
dose 250 mg), then increased if necessary up to
10 mg/kg twice daily (max. per dose 500 mg), dose to be
increased according to blood concentration and
response
▶Child 12–17 years:Initially 250 mg every 12 hours for
2 weeks, then increased if necessary up to 500 mg every
12 hours, dose to be increased according to blood
concentration and response
PHARMACOKINETICS
▶Cycloserine penetrates the CNS.lUNLICENSED USELicensed for use in children (age range
not specified by manufacturer).
lCONTRA-INDICATIONSAlcohol dependence.depression.
epilepsy.psychotic states.severe anxiety
lINTERACTIONS→Appendix 1 : cycloserine
lSIDE-EFFECTSBehaviour abnormal.coma.confusion.
congestive heart failure.drowsiness.dysarthria.
headache.hyperirritability.megaloblastic anaemia.
memory loss.neurological effects.paraesthesia.paresis.
psychosis.rash.reflexes increased.seizures.suicidal
ideation.tremor.vertigo
SIDE-EFFECTS, FURTHER INFORMATION
CNS toxicityDiscontinue or reduce dose if symptoms of
CNS toxicity occur.
Rashes or allergic dermatitisDiscontinue or reduce dose
if rashes or allergic dermatitis develop.
lPREGNANCYManufacturer advises use only if potential
benefit outweighs risk—crosses the placenta.
lBREAST FEEDINGPresent in milk—amount too small to be
harmful.
lRENAL IMPAIRMENT
Dose adjustmentsIncrease interval between doses if
creatinine clearance less than 50 mL/minute/ 1. 73 m^2.
MonitoringMonitor blood-cycloserine concentration if
creatinine clearance less than 50 mL/minute/ 1. 73 m^2.
lMONITORING REQUIREMENTS
▶Blood concentration should not exceed a peak
concentration of 30 mg/litre (measured 3 – 4 hours after the
dose).
▶Monitor haematological, renal, and hepatic function.366 Bacterial infection BNFC 2018 – 2019
Infection5